SABCS 2022: Trials Show Improved Outcomes in HR+, HER2- Breast Cancer
The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.
The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.
Differences in tumor characteristics could explain sex- and race-based disparities in patients with metastatic non-small cell lung cancer.
As many as 10% of early-onset metastatic colorectal cancer cases may be attributable to undiagnosed inflammatory bowel disease, a study suggests.
Two new studies shed light on the complexity of preventing subsequent breast cancer events in patients with ductal carcinoma in situ.
At a SITC summit, stakeholders identified administrative, staffing, and other barriers that impede progress in clinical cancer research.
A novel blood test can detect cancers that currently have no standard screening procedures, a study suggests.
New data highlight the high cost of targeted oral anticancer medicines for patients with Medicare Part D coverage.
Sublobar resection is noninferior to a full lobectomy in patients with carefully staged cT1aN0 non-small cell lung cancer, new research suggests.
An expert outlines ways to improve outcomes for older patients with ovarian cancer.
The expansion of Medicaid eligibility was associated with a nearly 3-fold increase in the proportion of Medicaid-covered patients enrolled in cancer treatment trials.